
CCCC
Healthcare · Biotechnology · $362.4M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +26.0% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | Before the open | -0.20 | -0.16 | +20.0% |
| Aug 11, 2026 | Before the open | -0.23 | -0.18 | +21.7% |
| May 12, 2026 | Before the open | -0.26 | -0.20 | +23.1% |
| Feb 26, 2026 | Time not confirmed | -0.43 | -0.18 | +58.1% |
| Nov 6, 2025 | Before the open | -0.39 | -0.30 | +23.1% |
| Aug 7, 2025 | Before the open | -0.38 | -0.37 | +2.6% |
| May 7, 2025 | Before the open | -0.43 | -0.37 | +14.0% |
| Feb 20, 2025 | Before the open | -0.45 | -0.49 | -8.8% |
| Oct 31, 2024 | Before the open | -0.33 | -0.35 | -6.1% |
| Aug 1, 2024 | Before the open | -0.18 | -0.26 | -44.4% |
| May 8, 2024 | Before the open | -0.26 | -0.38 | -46.2% |
| Feb 22, 2024 | Before the open | -0.68 | -0.70 | -2.9% |
| Nov 1, 2023 | Before the open | -0.65 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate,…
| -0.54 |
| +16.9% |
| Aug 8, 2023 | Before the open | -0.69 | -0.73 | -5.8% |
| May 4, 2023 | Before the open | -0.75 | -0.71 | +5.3% |
| Feb 23, 2023 | Before the open | -0.74 | -0.77 | -4.1% |
| Nov 3, 2022 | Before the open | -0.61 | -0.65 | -6.6% |
| Aug 4, 2022 | Before the open | -0.63 | -0.56 | +11.1% |
| May 5, 2022 | Before the open | -0.58 | -0.65 | -12.1% |
| Feb 24, 2022 | Before the open | -0.58 | -0.31 | +46.6% |
| Nov 10, 2021 | After the close | -0.56 | -0.51 | +8.9% |
| Aug 11, 2021 | After the close | -0.56 | -0.51 | +8.9% |
| May 13, 2021 | After the close | -0.63 | -0.49 | +22.2% |
| Mar 11, 2021 | After the close | -0.53 | -0.04 | +92.5% |
| Nov 12, 2020 | After the close | -0.36 | -0.63 | -75.0% |
| Sep 2, 2020 | Time not confirmed | — | -0.10 | — |